Australian Clinical Labs (ASX:ACL) Quality Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:ACL Australian Clinical Labs Ltd ASX:ACL
56 GF Score
Price A$2.38
GF Value A$3.06
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Australian Clinical Labs Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Australian Clinical Labs Quality Rank Related Terms

ASX:ACL
56GF Score
Australian Clinical Labs Ltd ASX:ACL
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Australian Clinical Labs (ASX:ACL) Overvalued in 2026?

Based on GuruFocus' analysis, Australian Clinical Labs stock appears to be undervalued. The current stock price of A$2.38 is trading 22.2% below its estimated GF Value™ of A$3.06. GuruFocus considers Australian Clinical Labs to be Modestly Undervalued.

Key valuation signals for ASX:ACL:

  • Quality Rank:
  • GF Value™: A$3.06 vs. price of A$2.38 (22.2% below fair value)
  • GF Score™: 56/100 with 5 warning signs

No single metric tells the full story. See the ASX:ACL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Australian Clinical Labs Business Description

Address 1868-1892 Dandenong Road, Clayton, VIC, AUS, 3168
Australian Clinical Labs is Australia's third-largest private pathology provider. ACL earns almost its entire group revenue from pathology services in Australia, which are mostly earned via the publicly funded health Medicare system. ACL is well established in the states of Western Australia, South Australia, Victoria, and the Northern Territory.
56GF Score

Get the complete analysis for ASX:ACL

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$2.38
Price
A$3.06
GF Value